Enlivex (ENLV) Operating Expenses (2013 - 2025)
Enlivex (ENLV) posted Operating Expenses of $5.9 million for Q4 2025, up 129.21% on a QoQ basis from $2.6 million in Q3 2025, and up 6.93% year-over-year from $5.5 million in Q4 2024.
Analysis
Enlivex (ENLV) Operating Expenses (2013 - 2025) Analysis & Trends
Enlivex has reported Operating Expenses for 13 years, with the latest figure at $5.9 million in Q4 2025.
- On a quarterly basis, Operating Expenses rose 6.93% year-over-year to $5.9 million in Q4 2025; TTM through Dec 2025 was $15.0 million, a 3.45% decrease from a year earlier, with the FY2025 full-year figure at $15.0 million, down 5.41% from the prior year.
- Operating Expenses was $5.9 million for Q4 2025 at Enlivex, up from $2.6 million in the prior quarter.
- The five-year high for Operating Expenses was $7.8 million in Q4 2022, with the low at $2.6 million in Q3 2025.
- Average Operating Expenses over 5 years is $5.0 million, with a median of $5.6 million recorded in 2023.
- The sharpest annual moves came in 2021 and 2024: Operating Expenses surged 111.36% in 2021, then tumbled 55.09% in 2024.
- Over 5 years, Operating Expenses stood at $7.8 million in 2021, then climbed by 0.4% to $7.8 million in 2022, then declined by 22.36% to $6.1 million in 2023, then dropped by 10.01% to $5.5 million in 2024, then gained by 6.93% to $5.9 million in 2025.
- The last three Operating Expenses figures came in at $5.9 million (Q4 2025), $2.6 million (Q3 2025), and $3.1 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Enlivex | 3.17 Mn | -2.59 Mn | - | 5.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 5.86 Mn |
| Sep 30, 2025 | 2.56 Mn |
| Jun 30, 2025 | 3.08 Mn |
| Mar 31, 2025 | 3.50 Mn |
| Dec 31, 2024 | 5.48 Mn |
| Sep 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Mar 31, 2024 | 3.95 Mn |
| Dec 31, 2023 | 6.09 Mn |
| Sep 30, 2023 | 5.63 Mn |
| Jun 30, 2023 | 6.65 Mn |
| Mar 31, 2023 | 6.78 Mn |
| Dec 31, 2022 | 7.85 Mn |
| Sep 30, 2022 | 5.68 Mn |
| Jun 30, 2022 | 5.87 Mn |
| Mar 31, 2022 | 6.40 Mn |
| Dec 31, 2021 | 7.81 Mn |
| Sep 30, 2021 | 3.86 Mn |
| Jun 30, 2021 | 3.81 Mn |
| Mar 31, 2021 | 3.80 Mn |